We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $239.46, moving +1.33% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.21% for the day. Elsewhere, the Dow saw an upswing of 1.03%, while the tech-heavy Nasdaq depreciated by 0.22%.
The kidney dialysis provider's stock has climbed by 7.56% in the past month, exceeding the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 4, 2026. The company is predicted to post an EPS of $4.01, indicating a 35.93% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $3.53 billion, up 4.53% from the prior-year quarter.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $15.07 per share and revenue of $14.3 billion. These results would represent year-over-year changes of +39.8% and +4.78%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare currently has a Zacks Rank of #3 (Hold).
Looking at valuation, DaVita HealthCare is presently trading at a Forward P/E ratio of 15.68. This signifies a discount in comparison to the average Forward P/E of 21 for its industry.
One should further note that DVA currently holds a PEG ratio of 0.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 1.7.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 86, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $239.46, moving +1.33% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.21% for the day. Elsewhere, the Dow saw an upswing of 1.03%, while the tech-heavy Nasdaq depreciated by 0.22%.
The kidney dialysis provider's stock has climbed by 7.56% in the past month, exceeding the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 4, 2026. The company is predicted to post an EPS of $4.01, indicating a 35.93% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $3.53 billion, up 4.53% from the prior-year quarter.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $15.07 per share and revenue of $14.3 billion. These results would represent year-over-year changes of +39.8% and +4.78%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare currently has a Zacks Rank of #3 (Hold).
Looking at valuation, DaVita HealthCare is presently trading at a Forward P/E ratio of 15.68. This signifies a discount in comparison to the average Forward P/E of 21 for its industry.
One should further note that DVA currently holds a PEG ratio of 0.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 1.7.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 86, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.